Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 7Myeloid 3Lymphoid 3

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Myeloproliferative Disorders 1Leukemia, Myeloid, Chronic-Phase 1

Interventions

Cyclophosphamide 143fludarabine phosphate 130Busulfan 109Tacrolimus 94fludarabine 93Mycophenolic Acid 90Whole-Body Irradiation 84Peripheral Blood Stem Cell Transplantation 81Imatinib Mesylate 69Antilymphocyte Serum 67Cyclosporine 66Azacitidine 64Cytarabine 63Methotrexate 60Melphalan 60Filgrastim 50Granulocyte Colony-Stimulating Factor 40Decitabine 40Thiotepa 38thymoglobulin 34Stem Cell Transplantation 34Dasatinib 34Radiotherapy 33nilotinib 31ruxolitinib 28Cord Blood Stem Cell Transplantation 28venetoclax 26Clofarabine 25Specimen Handling 24Methylprednisolone 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × olverembatinib × Myeloid × Clear all
NCT06817720 2026-05-20

Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

M.D. Anderson Cancer Center

Phase 2 Recruiting
50 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT04126681 2025-03-03

A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase

Ascentage Pharma Group Inc.

Phase 2 Completed
144 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase

NCT05521204 2022-08-30

Olverembatinib for FGFR1-rearranged Neoplasms

The First Affiliated Hospital of Soochow University

Phase 2 Recruiting
20 enrolled
Myeloid

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡